GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$41.18 USD
+0.86 (2.13%)
Updated Aug 13, 2024 04:00 PM ET
Pre-Market: $41.08 -0.10 (-0.24%) 9:20 AM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.18 USD
+0.86 (2.13%)
Updated Aug 13, 2024 04:00 PM ET
Pre-Market: $41.08 -0.10 (-0.24%) 9:20 AM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
Zacks News
Gilead (GILD) Beats on Q3 Earnings & Sales, Lowers '20 View
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the third quarter owing to Veklury sales. However, the company lowers annual guidance.
Company News for Oct 29, 2020
by Zacks Equity Research
Companies In The News Are: GE, MA, SNE, GSK.
Glaxo (GSK) Beats Earnings Estimates in Q3, Revenues Miss
by Zacks Equity Research
Glaxo beats earnings estimates in the third quarter of 2020 but misses the same for revenues. Stock down.
Drug/Biotech Stock Q3 Earnings on Oct 28: GSK, AMGN & More
by Zacks Equity Research
Let us take a look at four drug/biotech companies due to release their quarterly results on Oct 28.
Why GlaxoSmithKline (GSK) Might Surprise This Earnings Season
by Zacks Equity Research
GlaxoSmithKline (GSK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will AbbVie (ABBV) Q3 Earnings Recover From Coronavirus Woes?
by Zacks Equity Research
Investors will focus on any recovery in AbbVie's (ABBV) sales amid the coronavirus pandemic when it reports third-quarter results.
Roche (RHHBY) Inks Deal to Develop Oral Coronavirus Treatment
by Zacks Equity Research
Roche (RHHBY) signs a contract with privately-held Atea Pharmaceuticals for jointly developing AT-527, an oral treatment for COVID-19 patients.
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Pharmaceutical and Consumer Healthcare segments are likely to have driven third-quarter sales. Results will provide clarity on the impact of coronavirus on the company's vaccine business.
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $35.35 in the latest trading session, marking a -1.91% move from the prior day.
Merck (MRK) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.
Merck (MRK) Pneumococcal Vaccine Meets Late-Stage Study Goals
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.
Will Lilly (LLY) Witness Recovery in Sales in Q3 Earnings?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) third-quarter sales.
Aptinyx (APTX) Surges on Promising Stress Disorder Study Data
by Zacks Equity Research
Aptinyx (APTX) is developing a NMDA receptor-targeted candidate, NYX-783, as potential treatment for post-traumatic stress disorder.
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, in the Biopharma segment are likely to have made up for lower sales in the Upjohn group in the third quarter.
5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.
Sanofi's mRNA Vaccine for Coronavirus to Enter Clinical Stage
by Zacks Equity Research
Sanofi (SNY) and Translate Bio select coronavirus vaccine candidate MRT5500 for clinical development, based on its promising pre-clinical data. A clinical study is anticipated by this year-end.
Merck's Keytruda Gets FDA Nod for Expanded Use in Lymphoma
by Zacks Equity Research
The FDA approves Merck's (MRK) Keytruda for the treatment of adult patients with relapsed or refractory cHL who progress after frontline therapy.
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
Do J&J's Q3 Results Indicate a Sales Recovery for Big Pharma?
by Kinjel Shah
Investors typically look at J&J's (JNJ) results for signals regarding how the rest of the big drugmakers will fare.
Sanofi's Dupixent Meets All Goals in Asthma Study for Children
by Zacks Equity Research
Sanofi's (SNY) blockbuster drug Dupixent meets primary as well as all key secondary goals in a late-stage study for treating moderate-to-severe asthma in children aged six-11 years.
Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and AstraZeneca (AZN) provide updates on their coronavirus vaccine/treatment programs.
Vir Biotech, Glaxo Begin Phase III Study on Coronavirus Therapy
by Zacks Equity Research
Vir Biotechnology (VIR) and British partner Glaxo announce the global expansion of their COMET-ICE study on the COVID-19 antibody candidate VIR-7831 to phase III.
SpringWorks Inks Deal With Pfizer for Nirogacestat Combo
by Zacks Equity Research
SpringWorks (SWTX) inks a collaboration deal with Pfizer to evaluate nirogacestat along with the latter's BCMA-targeted therapy PF-06863135 for treating relapsed/refractory multiple myeloma. Stock up.
Pharma Stock Roundup: FDA Approves New Uses of PFE, JNJ & GSK's Drugs
by Kinjel Shah
New indications of Glaxo's (GSK) Nucala J&J's (JNJ) Simponi Aria and Pfizer's (PFE) Xeljanz get FDA's nod.
Glaxo Gets FDA Nod for Nucala for Hypereosinophilic Syndrome
by Zacks Equity Research
Glaxo's (GSK) Nucala becomes the first and only targeted biologic treatment to be approved for hypereosinophilic syndrome (HES), a rare disease caused by eosinophilic inflammation.